Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 May 2021 | Story Nonsindiso Qwabe | Photo Supplied
Puseletso Moqomo

A tale of sheer resistance and of never giving up, is what best describes University of the Free State student Puseletso Moqomo’s academic journey.

From changing studies three times, losing NSFAS funding, and not being able to pay her fees, to working as a cashier at a Bloemfontein filling station to fund her education, Moqomo has seen and done it all, and she says she wouldn’t change a single thing about her journey.

She received her Bachelor of Science degree in Microbiology and Genetics in the Faculty of Natural and Agricultural Sciences during the 2021 April virtual graduation ceremony. When asked what kept her going, she said, “I told myself that I would study hard and obtain my degree; no matter what came my way, I wouldn’t give up. I would be tired and unable to study, but I told my mind that I had to do what I had to do to advance.”

Moqomo first encountered financial exclusion when her application for NSFAS funding was not approved in 2016. She did not have the R6 830 that was required for registration, and therefore had to pause her studies indefinitely. She decided to look for a job to pay her fees, and in June of that year she was employed as a temporary cashier at the Engen filling station at Northridge Mall in Noordhoek. “I was embarrassed and ashamed when I lost my NSFAS funding but giving up was not one of the things on my mind. When I started working, I made it very clear that I didn’t want to be a permanent employee; I simply wanted to work enough to have money to pay my fees.”

Juggling work and school paid off 

She saved enough to be able to register again in January 2017, but she had to change degree programmes along the way. “After writing my November exams, I would go back to Engen so that I could save money for the following year’s registration. I would fail my modules but still try again,” she said.

NSFAS continued to pay for the rest of her fees, but in 2020, during her final year, she was told that she had exceeded the number of years she could receive funding. “I began working full time because I knew I might not get NSFAS funding even after appealing, so I would work night shifts from Friday to Sunday, then take a bath at work and go to class on Monday mornings. Through all of this, I told myself that I would pass, and I would pass well.”

Fortunately, after relating her whole story to NSFAS during her appeal, she received funding for her final year – which came on time too, as she had to be laid off work temporarily due to the COVID-19 pandemic. She went back to work again in November 2020 and saved enough money to register for a Postgraduate Certificate in Education (PGCE), which she is currently pursuing. She is also currently completing her teaching practical at Ikaelelo Senior Secondary School, where she matriculated in 2013. “I knew I wanted to continue with my studies, so I worked hard.”

“Giving up is not an option; some things do not come easily – not even a degree. For some it might be easy, but for others there will be hurdles that they will have to overcome, but you have to keep going.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept